The Pharma Data

SEPTEMBER 11, 2021

Results from EMPEROR-Preserved were presented at the European Society of Cardiology Congress 2021 on August 27 and published in The New England Journal of Medicine. vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. drowsiness.

Medicine 52

Medicine Insulin FDA Approval Trials 52

The Pharma Data

JULY 8, 2021

. “No approved therapies have been clinically proven to improve outcomes specifically for people with HFpEF, leaving a significant unmet medical need in this already prevalent and increasingly common form of heart failure,” said Mohamed Eid, M.D., vice president, Product Development, Lilly. Source link: [link].

Trials 52

Trials Doctor Doctors Medicine 52

XTalks

AUGUST 2, 2023

It is a dipeptidyl peptidase-4 inhibitor that keeps insulin levels stable and reduces the amount of glucose produced by the body. In partnership with Seagen, Sanofi will design, develop and commercialize ADCs for three cancer targets using Sanofi’s proprietary monoclonal antibody technology and Seagen’s proprietary ADC technology.

Sales 98

Sales Manufacturing FDA Approval Life Science 98